


### Anti-Parkin antibody ab15494

**5 References** [画像数 1](#)

#### 製品の概要

製品名	Anti-Parkin antibody
製品の詳細	Rabbit polyclonal to Parkin
由来種	Rabbit
アプリケーション	<b>適用あり:</b> ICC/IF, IHC-P
種交差性	<b>交差種:</b> Human <b>交差が予測される動物種:</b> Mouse, Rat 
免疫原	Synthetic peptide within Human Parkin aa 50-150 (N terminal). The exact sequence is proprietary.
ポジティブ・コントロール	Recombinant Human Parkin protein ( <a href="#">ab114219</a> ) can be used as a positive control in WB. IHC-P: Human brain tissue.
特記事項	<p><b>This product is FOR RESEARCH USE ONLY. For commercial use, please contact <a href="mailto:partnerships@abcam.com">partnerships@abcam.com</a>.</b></p> <p>The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.</p> <p>If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&amp;As</p>

#### 製品の特性

製品の状態	Liquid
保存方法	Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
バッファー	pH: 7.60 Preservative: 0.1% Sodium azide Constituents: PBS, 1% BSA
精製度	Immunogen affinity purified
ポリ/モノ	ポリクローナル
アイソタイプ	IgG

## アプリケーション

**The Abpromise guarantee**      **Abpromise保証は、次のテスト済みアプリケーションにおけるab15494の使用に適用されます**  
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご確認ください。

アプリケーション	Abreviews	特記事項
ICC/IF		Use at an assay dependent concentration.
IHC-P		1/30. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

## ターゲット情報

機能	Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene.
組織特異性	Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis. Found in serum (at protein level).
パスウェイ	Protein modification; protein ubiquitination.
関連疾患	Defects in PARK2 are a cause of Parkinson disease (PARK) [MIM:168600]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

Defects in PARK2 are the cause of Parkinson disease type 2 (PARK2) [MIM:600116]; also known as early-onset parkinsonism with diurnal fluctuation (EPDF) or autosomal recessive juvenile Parkinson disease (PDJ). A neurodegenerative disorder characterized by bradykinesia, rigidity, postural instability, tremor, and onset usually before 40. It differs from classic Parkinson disease by early DOPA-induced dyskinesia, diurnal fluctuation of the symptoms, sleep benefit, dystonia and hyper-reflexia. Dementia is absent. Pathologically, patients show loss of dopaminergic neurons in the substantia nigra, similar to that seen in Parkinson disease; however, Lewy bodies (intraneuronal accumulations of aggregated proteins) are absent. Note=Defects in PARK2 may be involved in the development and/or progression of ovarian cancer.

#### 配列類似性

Belongs to the RBR family. Parkin subfamily.  
Contains 1 IBR-type zinc finger.  
Contains 2 RING-type zinc fingers.  
Contains 1 ubiquitin-like domain.

#### ドメイン

The ubiquitin-like domain binds the PSMD4 subunit of 26S proteasomes.


#### 翻訳後修飾

Auto-ubiquitinates in an E2-dependent manner leading to its own degradation. Also polyubiquitinated by RNF41 for proteasomal degradation.  
S-nitrosylated. The inhibition of PARK2 ubiquitin E3 ligase activity by S-nitrosylation could contribute to the degenerative process in PD by impairing the ubiquitination of PARK2 substrates.

#### 細胞内局在

Cytoplasm > cytosol. Nucleus. Endoplasmic reticulum. Mitochondrion. Mainly localizes in the cytosol. Co-localizes with SYT11 in neurites. Co-localizes with SNCAIP in brainstem Lewy bodies. Relocates to dysfunctional mitochondria that have lost the mitochondrial membrane potential; recruitment to mitochondria is PINK1-dependent.

#### 画像



ab15494 staining Parkin in Alzheimers brain by Immunohistochemistry (FFPE-sections).

**Please note:** All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

**Our Abpromise to you: Quality guaranteed and expert technical support**

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.co.jp/abpromise> or contact our technical team.

#### **Terms and conditions**

---

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors